SingleBioregulators

Livagen 20mg

A synthetic Khavinson tetrapeptide investigated for liver bioregulation, epigenetic modulation, and chromatin decondensation in aging models.

Mechanism

Livagen is theorized to promote epigenetic reactivation via direct chromatin decondensation, potentially restoring transcription of previously repressed genes in senescent cells.

Dosing

Standard laboratory protocols document an initial daily research dose of 500 mcg administered subcutaneously during introductory phases.

Reconstitution

Reconstituting a 20 mg vial with 3.0 mL of bacteriostatic water yields an approximate working concentration of 6.67 mg/mL (66.7 mcg per U-100 unit).

Storage

Store the unmixed lyophilized powder frozen at -20 °C, and once dissolved, keep the vial refrigerated between 2 °C and 8 °C protected from light without refreezing.

Mix & measure Livagen 20mg

Pre-filled with this protocol's recommended BAC water and documented starting dose — edit any field to run your own numbers.

Mix & measure Livagen 20mg

Vial strength → BAC water → target dose

Vial strength

BAC water

Target dose

Concentration6.67mg/mL

Draw volume0.075mL

On the syringe7.50units

Total doses in vial: 40.0

100u80u60u40u20u0

U-100 syringe: 100 units = 1 mL

Reconstitution math only — not dosing advice. U-100 syringe: 100 units = 1 mL. Advanced calculator →

Dosing Chart

Phase / Day(s)	Dose & Frequency	Volume (U-100 units / mL)
Weeks 1–2	500 mcg (1× daily)	~7.5 units (~0.075 mL)
Weeks 3–4	1,000 mcg (1× daily)	15 units (0.15 mL)
Weeks 5–6	1,500 mcg (1× daily)	~23 units (~0.225 mL)
Weeks 7–12	2,000 mcg (1× daily)	30 units (0.30 mL)

Reconstitution Steps

1
Draw exactly 3.0 mL of bacteriostatic water into a fresh sterile syringe.
2
Gently inject the diluent along the interior glass wall of the 20 mg Livagen vial to prevent aggressive agitation.
3
Slowly roll or swirl the vial between your fingers until all peptide cake is completely dissolved; never shake vigorously.
4
Clearly label the reconstituted vial with the date and concentration, then refrigerate at 2–8 °C away from light.

Supplies Needed

Peptide Vial

Supplies the lyophilized Livagen peptide (20 mg per container) for investigative reconstitution.

Insulin Syringes (U-100)

Enables accurate fluid volumetric measurement of micro-doses using standard 100-unit graduations.

Bacteriostatic Water

Serves as the sterile, preserved diluent required to reconstitute the peptide cake safely for multi-dose usage.

Alcohol Swabs

Ensures proper aseptic handling by disinfecting vial stoppers and contact surfaces prior to puncture.

Why researchers study it

Hepatic tissue bioregulation and liver support

Chromatin decondensation and transcriptional reactivation

Cellular senescence and longevity pathways

Immune cell modulation and lymphocyte activity

These describe what is being studied, not proven benefits, approved uses, or promised results.

Overview

Livagen is a synthetic short-chain peptide composed of four amino acids (Lys-Glu-Asp-Ala, or KEDA). Classified under the Khavinson group of peptide bioregulators, it is primarily examined for its prospective tissue-specific affinity toward hepatic cells and immune system components. Originally designed through Russian gerontological research programs, this tetrapeptide remains an experimental subject for understanding cellular regulation across aging models. In preclinical laboratory literature, Livagen is evaluated for its capacity to influence nuclear architecture and reverse age-associated transcriptional silencing. By interacting with core genetic machinery, it is hypothesized to stimulate cellular renewal pathways without acting as a conventional synthetic stimulant or receptor agonist. To date, Livagen is not approved by major regulatory bodies, such as the FDA or EMA, for any clinical indication or therapeutic use. Scientific understanding relies almost entirely on preliminary cellular cultures and animal studies, and the compound is maintained solely for laboratory investigation and reference benchmarking.

References

1.Khavinson et al., Biogerontology, 2002 — Peptides and ageing: short-peptide bioregulators including Livagen (KEDA)
2.Khavinson et al., Bull. Exp. Biol. Med., 2003 — Livagen peptide sequence and in-vitro effects on lymphocyte chromatin
3.Anisimov & Khavinson, Biogerontology, 2010 — Review of peptide bioregulation of aging and short peptides
4.Khavinson et al., Bull. Exp. Biol. Med., 2000 — Epigenetic chromatin decondensation and gene reactivation by short peptides